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Abstract
Objective
We determined, for packed red blood cells (PRBC) and fresh frozen plasma, the maximum
content, and ability to release the endogenous nitric oxide synthase (NOS) inhibitors asym-
metric dimethylarginine (ADMA) and monomethylarginine (LNMMA).
Background
ADMA and LNMMA are near equipotent NOS inhibitors forming blood’s total NOS inhibitory
content. The balance between removal from, and addition to plasma determines their free
concentrations. Removal from plasma is by well-characterized specific hydrolases while for-
mation is restricted to posttranslational protein methylation. When released into plasma
they can readily enter endothelial cells and inhibit NOS. Fresh rat and human whole blood
contain substantial protein incorporated ADMA however; the maximum content of ADMA
and LNMMA in PRBC and fresh frozen plasma has not been determined.
Methods
Wemeasured total (free and protein incorporated) ADMA and LNMMA content in PRBCs
and fresh frozen plasma, as well as their incubation induced release, using HPLC with fluo-
rescence detection. We tested the hypothesis that PRBC and fresh frozen plasma contain
substantial inhibitory methylarginines that can be released chemically by complete in vitro
acid hydrolysis or physiologically at 37°C by enzymatic blood proteolysis.
Results
In vitro strong-acid-hydrolysis revealed a large PRBC reservoir of ADMA (54.5 ± 9.7 µM)
and LNMMA (58.9 ± 28.9 μM) that persisted over 42-d at 6° or -80°C. In vitro 5h incubation
at 37°C nearly doubled free ADMA and LNMMNA concentration from PRBCs while no
change was detected in fresh frozen plasma.
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Conclusion
The compelling physiological ramifications are that regardless of storage age, 1) PRBCs
can rapidly release pathologically relevant quantities of ADMA and LNMMA when incubated
and 2) PRBCs have a protein-incorporated inhibitory methylarginines reservoir 100 times
that of normal free inhibitory methylarginines in blood and thus could represent a clinically
relevant and proximate risk for iatrogenic NOS inhibition upon transfusion.
Introduction
Endogenous inhibition of nitric oxide synthase (NOS) is linked to clinically relevant, dose-
dependent pathologies such as ischemic vasoconstriction [1], platelet aggregation [2], and mye-
loperoxidase release [3]. The ability of asymmetric dimethylarginine (ADMA) and mono-
methylarginine (LNMMA) (Fig. 1) to inhibit all isoforms of NOS is firmly established [4], as is
the function of NOS to produce NO. Historical nitro-vasodilators such as nitroglycerin and so-
dium nitroprusside were linked by Murad’s group [5] to endothelial derived relaxing factor
and subsequently to NO mediated endothelial vascular relaxation [6] establishing central phys-
iological and pathophysiological roles for NOS and for this study of potential NOS-inhibition.
This pathway involves free arginine as the normal substrate for NOS producing NO and both
ADMA and LNMMA as near equipotent competitive (Ki ~ 1 μM) endogenous inhibitors of
NOS [4]. Specifically, Leiper and Vallance described the IC50 values for L-NMMA and ADMA
for NOS (all three forms) as being “approximately equipotent” [7] and “on the order of 2 to
5 μM”. Tsikas et al., stated, “ADMA and NMA (L-NMMA) inhibit NO synthesis with compa-
rable potencies in vitro and in vivo, in blood vessels, and macrophages in animals and in man.”
[8], while Cardounel et al., used a combination of cell culture work, vascular reactivity studies
and in vivo carotid artery injury techniques [4] to reveal the Ki of ADMA and L-NMMA to be
0.9 and 1.1 μM respectively. Both ADMA and LNMMA are primarily cleared from the blood
by hydrolysis by dimethylarginine dimethylaminohydrolase (DDAH) [9, 10] and to a lesser de-
gree by the kidneys.
Fig 1. Arginine and its endogenousmethylated derivatives. Arginine is the normal substrate for NOS
resulting in NO formation. A single methylation of arginine produces monomethylarginine (LNMMA) which,
along with asymmetric dimethylarginine (ADMA), are endogenous inhibitors of NOS. ADMA and LNMMA are
hydrolyzed by dimethylarginine dimethylaminohydrolase (DDAH). Symmetric dimethylarginine does not
inhibit NOS. These structures were drawn as they exist at mammalian physiological pH using ChemDraw
software (PerkinElmer Informatics) and data from PubChem at NCBI at the National Library of Medicine
(USA).
doi:10.1371/journal.pone.0119991.g001
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Blood is a bulk carrier of ADMA and LNMMA and we propose that blood may also act as
their primary physiological source. The presence, concentrations, and release potential of these
inhibitors in commercially available packed red blood cells (PRBC) and fresh frozen plasma, in
contrast to fresh blood and plasma, is unknown. Both inhibitors are found free in plasma
(< 0.5 μM) and are widely incorporated in proteins in fresh animal (43 μM)[11] and human
whole blood (36 μM) [12]. Total molar concentration of these amino acid inhibitors can be de-
termined by strong acid hydrolysis to individual amino acids. The potentially releasable store of
NOS inhibitors can be calculated by subtraction of the free-in-plasma concentration of ADMA
and LNMMA from the total concentration (including incorporated). It follows that when the
total store of ADMA and LNMMA is many (100X) times that of plasma, then the ongoing nor-
mal proteolysis of even a small fraction of the store will add to the systemic circulating burden
of NOS inhibition. The specific tissues or proteins that serve as the origin for elevated circulating
ADMA and LNMMA have yet to be defined for PRBC's and fresh frozen plasma.
The point of this study was to investigate the impact of storage on PRBC inhibitory methy-
larginine total content. PRBCs are commercially available, derived blood products, separated
by centrifugation and size exclusion techniques and then mixed with a large number of preser-
vation agents. They are kept under non-physiological conditions in polyvinylchloride bags
made flexible with phthalate esters [13], have a finite shelf life, and thus they are different from
fresh whole blood. We determined if stored PRBCs and fresh frozen plasma could serve as a di-
rect source of ADMA and LNMMA by virtue of containing proteins that incorporate patholog-
ically significant quantities of these releasable inhibitory methylarginines. Once subjected to
proteolytic breakdown, these proteins would release ADMA and LNMMA into solution (in
plasma) and be available for inhibition of NOS. In high blood product use areas in critical care,
many seemingly disparate injury modalities (trauma, multiple organ failure, and sepsis) utilize
shared, leukocyte-based inflammatory-pathologic pathways [14, 15]. This elevated and often
ongoing inflammatory state could provide the conditions necessary for enhanced proteolytic
release of these NOS inhibitors. Specifically, we wanted to determine the theoretical maximum
capacity of these blood products to release free inhibitory methylarginines and thus their ability
to contribute the total NOS inhibitor burden. However, in this study we did not address the
eventual in vivo (following transfusion) formation and release of inhibitory methylarginines
nor their likely deleterious effects on NO bioavailability. We did, however, clearly establish a
potential and previously unidentified risk of NOS inhibition following PRBC transfusion.
Materials and Methods
Methods briefly described below are largely based upon our previous publications [3, 11, 12, 16].
Detailed descriptions are found in S1 Methods.
Blood components
All blood components (PRBC and fresh frozen plasma) were obtained from the University of
Michigan Health System Blood Bank, originated from the American Red Cross Blood Services,
Southeastern Michigan Region, and were stored in accordance with AABB Standards or experi-
mentally frozen at -80°C to completely inhibit normal enzymatic activity. Each PRBC unit was
Adenine—Saline Added, Leukocytes Reduced, Group O, and Rh positive, from different
male donors.
Ethics Statement
A University of Michigan Human Research Protection Program Institutional Review Board ap-
proval was not required for use of these de-identified commercial blood products.
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Strong Acid hydrolysis of blood proteins
Upon arrival and at 2, 4, and 6 weeks, well-mixed PRBC or fresh frozen plasma were sampled
using aseptic technique and acid hydrolyzed to release previously formed inhibitory methylat-
ed arginines [17] yielding total ADMA and LNMMA (i.e. the sum of free and protein-incorpo-
rated). This is thus a direct measurement of the total ADMA and LNMMA in the PRBC or
fresh frozen plasma samples. Samples were kept on ice and diluted with an ice-cold solution
containing NG-monoethyl-L-arginine monoacetate salt (MEA) as HPLC internal standard
[18]. 100 μL aliquots of 40-fold diluted PRBC or 2-fold diluted fresh frozen plasma were dried
in a centrifugal evaporator (GeneVac, EZ-Bio), placed in a hydrolysis chamber (Picotag, Wa-
ters, Milford, MA) containing 6 N HCl (constant boiling), and incubated in vacuo at 150°C for
1h and re-dried. These protein hydrolysates (free amino acids) were re-suspended in 100 μL of
20 mMHCl and supernatant was separated and analyzed by HPLC with fluorescence detec-
tion. Values were corrected for dilution and normalized to assayed hemoglobin
when appropriate.
Incubation Protocols
Blood contains enzymes capable of breaking down proteins to amino acids thus liberating any
incorporated methylated arginine. A 37°C water bath was used for incubation as this tempera-
ture is a reasonable approximation of in vivo conditions for generation of ADMA and
LNMMA previously demonstrated to occur by proteolytic release in both rat [11] and human
blood [12]. At multiple time points (0 to 6 wk.) after acquisition, PRBCs were lysed by three se-
rial freeze-thaw cycles to eliminate cell membrane diffusional barriers. Lysates were centrifuged
and supernatant was incubated at 37°C. Samples were taken at 0, 1, 3 and 5 h and analyzed for
ADMA and LNMMA by HPLC. Fresh frozen plasma was similarly processed.
Sample preparation for methylarginines assay and High-performance
liquid chromatography
Samples (100 μL) were prepared for HPLC analysis of methylarginines and were quantified
by reverse-phase liquid chromatography (Breeze System, Waters) as previously described
[3, 11, 12, 16] and detailed in S1 Methods.
Protein and Hemoglobin assay
Protein was quantified using the Pierce BCA [bicinchoninic acid] Protein Assay [Rockford, IL].
Bovine Gamma Globulin [BGG, Bio-Rad Product No. 500–0208 Hercules, CA] was used as a
protein standard according to manufacturer’s instructions. Absorbance [Bio-Rad SmartSpec
3000 Spectrophotometer] of eight standards was used to create a polynomial regression to
which sample absorbencies were applied to calculate protein concentrations.
Hemoglobin was quantified spectrophotometrically in alkaline hematin detergent complex
(D-575 AHD) using an effective millimolar extinction coefficient of 27.08 at 575 nm per heme
(ε575 = 6.77 ± 0.018). This method is reported by Fenchik, McFaul, and Tsonev [19] to give ex-
cellent agreement with assays based upon more traditional potassium ferricyanide and potassi-
um cyanide (Drabkin’s Reagent) [20] methodologies and is detailed in S1 Methods.
Catalase Evaluation as a source of ADMA in PRBC
Using the online protein database of the National Center for Biotechnology Information (U.S.
National Library of Medicine), the amino acid sequence of human catalase was analyzed to de-
termine the percent arginine content (http://www.ncbi.nlm.nih.gov/protein/NP_001743.1).
PRBC as Source of NOS Inhibition
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The analysis revealed 29 arginine residues present in the 527 amino acid protein sequence.
Thus, arginine accounts 5.5% of the sequence composition of human RBC-catalase; a well-
characterized soluble red blood cells cytosolic enzyme. To determine catalase concentration in
PRBC units we sampled duplicate aliquots from fresh, well-mixed PRBC bags (n = 2) and froze
them for shipment. At the analytical laboratory they were thawed, aliquoted, hemolysed, and
prepared for analysis using size exclusion chromatography and inductively coupled plasma
mass spectrometry (ICP-MS). Technique details are in S1 Methods.
ADMA Concentration in human catalase
Pure human catalase (Sigma Aldrich-Product Number C3556) was subjected to strong acid hy-
drolysis followed by HPLC direct quantification for ADMA as described above. Using data de-
rived from catalase concentration measured in PRBCs and the ADMA concentration
determined from pure catalase, we calculated the percent of total ADMA in PRBCs attributable
to catalase as detailed in S1 Methods.
Statistical analysis
Data are reported as mean ± one standard deviation (SD) and were analyzed using repeated
measures two-way analysis of variance. If significant differences were detected, data were fur-
ther evaluated using Tukey’s post-hoc multiple comparison test (α = 0.05). Incubation data
were evaluated using linear regression analysis to determine the relationship between incuba-
tion time and accumulation of ADMA. Significance for all tests was accepted at p 0.05.
Results
Acid hydrolysis releases total-MA from PRBC’s
We first determined the total NOS inhibitor content and relative stability in PRBCs over 42
days, and analyzed total (free plus protein incorporated) inhibitory methylarginines from sam-
ples stored under standard conditions (6°C) or frozen at -80°C to inhibit enzymatic activity.
Upon receipt, aliquots from each unit were prepared, with four maintained at 6°C and four at
-80°C to avoid repeated freeze thaw or warming cycles encountered by serial sampling at 0, 2,
4, and 6 weeks of the same sample over 42 days. Despite upward trends, no statistically signifi-
cant effect of storage time or temperature was detected. Our critical observation is that we
found, for the first time in PRBCs, an overall 42-day average (combined 6°C and -80°C values)
for total ADMA of 54.5 ± 9.7 μM (Fig. 2). This is in contrast to 36μM found in fresh human
blood reported previously [12] and is almost 100 times the free ADMAmeasured in these sam-
ples (0.58 ± 0.12 μM). By contrast, LNMMA averaged 58.9 ± 28.9 μM or over 700 times the
free LNMMA (0.08 ± 0.02 μM). Combined, total ADMA and LNMMA, represent a maximal
inhibitory methylarginines release capacity of 114 μM for hydrolyzed PRBC. The symmetric
dimethylarginine average was 132 ± 30 μM over this same period. When total ADMA was nor-
malized to g/hemoglobin (Fig. 3), the overall 42-day combined average (6°C and -80°C sam-
ples) appeared to be stable at an average (N = 8) of 0.33 ± 0.04 μmoles ADMA/g Hb. Thus
lysed PRBC contain a liberated inhibitory methylarginines reservoir two orders of magnitude
greater than the free inhibitory methylarginines in ready to transfuse PRBC. (Figs. 2 and 3).
Percent ADMA attributable to catalase
On average only 1.8% of the total ADMA found in PRBCs could be attributed by calculation to
the measured presence of catalase. Table 1 shows the individual hematologic values for PRBC
units sampled for catalase. The average value for μmol ADMA/ g catalase was determined
PRBC as Source of NOS Inhibition
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separately on pure human catalase following strong acid hydrolysis. This value multiplied by
the measured catalase concentration in g/L PRBC gave the estimated μmol ADMA/L of PRBC.
Incubation induced free-inhibitory methylarginines release from PRBC’s
We observed that 5h incubation of PRBC supernatant nearly doubled free ADMA in solution
(Fig. 4). Linear regression analysis revealed a positive, time-dependent accumulation of ADMA
in PRBCs and 1:1 mixture of PRBC: fresh frozen plasma (p = 0.0072 and p = 0.0388 respective-
ly). These PRBC-data are similar to, but distinct from, our initial observations of a similar re-
lease response based upon fresh freeze thawed rat whole blood [11] and fresh freeze thawed
human blood [12]. This PRBC-based observation is also different from that of Teerlink’s group
[21] who used fresh washed erythrocytes. However, the important consistency to note is that
incubation at 37°C effectively released inhibitory methylarginines from PRBCs, whole blood,
washed red blood cells or red blood cell lysates in each of these studies.
When fresh frozen plasma was thawed and incubated under identical conditions that re-
sulted in marked release of ADMA from PRBCs, we found (Fig. 4) no statistically significant
increase (open triangles) in released free ADMA. To simulate transfusion practice we also
Fig 2. Total methylarginines obtained by strong acid hydrolysis of pre-aliquoted PRBCs stored at 6°C
or -80°C. No statistically significant differences were detected between 6°C or -80°C storage at any time
(pooled to 5, 14, 28 and 42 d) for ADMA, LNMMA and symmetric dimethylarginine and no change from
control was detected. It is likely that neither PRMT activity nor DDAH-induced hydrolysis was a dominating
effect under these storage conditions. However, equal formation and hydrolysis cannot be ruled out.
doi:10.1371/journal.pone.0119991.g002
PRBC as Source of NOS Inhibition
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incubated equal parts PRBC supernatant mixed with thawed plasma (open circles) expecting a
50% reduction in ADMA release due to fresh frozen plasma dilution of the PRBC. To our sur-
prise, the 1:1 mixture yielded near identical concentrations of free ADMA. Assuming that,
within this 1:1 incubation mixture, the fresh frozen plasma fraction released no ADMA, then
the 50% diluted PRBC supernatant portion must have released the same quantity of ADMA as
the 100% PRBC solution. That is, twice the free ADMA was released from half the PRBCs. For
this to happen either more substrate was available to react in the 1:1 mixture and or greater hy-
drolytic activity was at work during this 5h period. We have not determined which mecha-
nisms are responsible for this relative increased release but do note the potential added NOS
inhibitor burden possible with such a response. We confirmed the 1:1 dilution by measuring
the hemoglobin concentration, which was halved (97 g/L vs. 192 g/L original PRBC), and thus
the other components of the PRBC supernatant would also be halved. The 1:3 (PRBC to fresh
Fig 3. ADMA scaled against hemoglobin concentration over storage time at 6°C or -80°C. In an attempt
to account for any dehydration of the samples under either storage condition (6°C or -80°C), we measured
hemoglobin concentrations paired with each ADMAmeasurement to calculate ADMA to hemoglobin ratio.
The time course and pattern remained unchanged over time suggesting no measurable desiccation effect on
sample concentration over the 42-day storage.
doi:10.1371/journal.pone.0119991.g003
Table 1. Hematologic values for PRBCs in Catalase experiment.
Sample Hct (%) Hb (g/L) PRBC protein
(g/L)
PRBC Catalase
(g/L)
PRBC ADMA
(μmol/L)
*ADMA/
Catalase (μmol/
g)
Catalase ADMA/
PRBC (μmol/L)
% ADMA due
to catalase
Unit 18.1 65.8 195.2 102.5 0.233 30.9 4.42 1.03 3.3
Unit 18.2 203.2 108.1 0.094 35.1 4.42 0.42 1.2
Unit 19.1 57.8 172.4 91.0 0.123 33.7 4.42 0.54 1.6
Unit 19.2 171.4 84.1 0.097 41.0 4.42 0.43 1.0
Mean ± SD 61.4 ±5.7 185.6 ± 16.1 96.4 ± 10.9 0.13 ± 0.066 35.2 ± 4.3 4.42 0.61 ±0.29 1.8 ±1.0
*The average value for μmol ADMA/ g catalase was determined separately on pure human catalase following strong acid hydrolysis. This value was
multiplied by the measured catalase concentration in g/L PRBC to give the estimated μmol ADMA/L of PRBC.
doi:10.1371/journal.pone.0119991.t001
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frozen plasma) dilution markedly attenuated the ADMA release response (open diamonds)
and suggests a trailing off of the release at five hours perhaps due to depletion of substrate
for proteolysis.
The baseline (Time = 0) steady-state PRBC concentrations of free ADMA (0.58 ± 0.12 μM),
symmetric dimethylarginine (0.20 ± 0.12 μM), and LNMMA (0.08 ± 0.02 μM) were different
so, we normalized each to their time zero baseline value and calculated response to incubation
as a fraction of baseline (Fig. 5). The ADMA data are the same as in Fig. 4 except expressed as a
fraction of baseline. The slope of the normalized release line is near identical for ADMA and
LNMMA while the symmetric dimethylarginine slope tends to be lower but is not statistically
different. Given that LNMMA and ADMA have been reported to be near equipotent NOS in-
hibitors [4] this robust release represents a significant source for circulating ADMA and
LNMMA.
Discussion
Potential Risk of NOS Inhibition Following PRBC Transfusion
In this study we report two novel and important findings: 1) fresh PRBCs contain a very large
reservoir of incorporated (bound) endogenous NOS inhibitors (Figs. 2 and 3); and 2) 37°C in-
cubation releases significant free amounts of both ADMA and LNMMA (Figs. 4 and 5) into
the supernatants regardless of the PRBC storage age at the start of incubation. Both
Fig 4. Incubation-induced release of Free ADMA over 5h by Blood Product type. Incubation of defrosted fresh frozen plasma (open triangles),
supernatants of PRBC alone (solid squares), a mixture of 1:1 PRBC and fresh frozen plasma (open circles), and a mixture of 1:3 PRBC and fresh frozen
plasma (open diamonds). Repeated measures Two-way ANOVA shows significant differences of ADMA among PRBC and PRBC: fresh frozen plasma
groups over the incubation period (p<0.006). Tukey’s post-hocmultiple comparison test revealed significant differences of ADMA (α = 0.05) among groups
at individual sampling points. At three and five hour time points, ADMA in PRBC and 1:1 PRBC: fresh frozen plasma was significantly (*) higher than 1:3
PRBC: fresh frozen plasma. Hemoglobin measurements confirmed PRBC concentration and dilutions.
doi:10.1371/journal.pone.0119991.g004
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observations indicate that PRBC’s used in transfusion have the capacity to increase the NOS in-
hibitory burden in the recipient following transfusion even if only<1% of bound (40 to
70 μM) ADMA and LNMMA were released as further discussed below.
The existence of blood borne endogenous NOS inhibitors is not new, however, demonstrat-
ing that PRBC transfusion products contain and have the capacity to release pathologically rel-
evant quantities of both ADMA and LNMMA is novel. This suggests a previously
unanticipated risk of PRBC transfusions. While normal control of vascular NOS activity by cir-
culating endogenous NOS inhibitors may have an important physiological role, excessive inhi-
bition of ubiquitous endothelial Nitric Oxide Synthase (eNOS), has the potential to increase
post-transfusion morbidity and mortality due to dysregulation of the critical vasodilator NO.
We examined PRBC and fresh frozen plasma as possible protein sources of ADMA and
LNMMA due to blood’s proximity to eNOS containing vascular endothelial cells. It is illustra-
tive to consider circulating blood as a large (~5 Kg) organ (or continually renewed reservoir) in
intimate contact with endothelial cells containing eNOS. When proteolysis of blood proteins
releases significant quantities of ADMA and LNMMA these endogenous inhibitors would have
almost immediate access to eNOS for inhibition.
ADMA and LNMMA Combined eNOS Inhibitor potential
Both ADMA and LNMMA were consistently present in fresh PRBC and throughout the stor-
age period and when added together present a 114 μM (55 + 59 μM) concentration of endoge-
nous NOS inhibitor potential. This is the first report of large quantities of LNMMA in addition
to ADMA in PRBC’s and thus identifies the maximum NOS inhibitory potential ever reported.
Physiological or pathophysiological release mechanisms, even amplified in the critically ill, are
not likely to ever approach this maximum release concentration. However, Teerlink’s group
[22] by prolonging the incubation period to 18h increased the total ADMA released to 60% of
total incorporated. If, following transfusion, as little as 0.5 to 1.0% of the incorporated amino
Fig 5. Relative methylated arginine release over 5 h from PRBC incubation. All three methylated
arginines, ADMA, LNMMA, and symmetric dimethylarginine were released in proportionately similar amounts
during the 5h incubation at 37°C. The starting free concentrations were different (0.58 ± 0.12, 0.08 ± 0.02, and
0.20 ± 0.12 respectively). Free ADMA, LNMMA and symmetric dimethylarginine increased significantly from
baseline by 5h. Linear regression analysis failed to detect differences amongmethylated arginines over 5h.
doi:10.1371/journal.pone.0119991.g005
PRBC as Source of NOS Inhibition
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acids were released by ongoing proteolytic breakdown it would double the plasma concentra-
tion in each unit administered. In a multi-unit transfusion scenario, pathological plasma levels
would rapidly be attained in the transfusion recipient. Adding a similar concentration of the
total LNMMA (~59μM) from the PRBC's would double the potential combined NOS inhibito-
ry potential of a PRBC transfusion.
Total content of inhibitory methylarginines in stored PRBC at 6° and
-80°C vs. fresh human blood
We first reported fresh whole blood from rats (43 μM) [11] contained significant incorporated
and hence total ADMA and subsequently showed that fresh whole blood from normal human
volunteers contained 36 μM [12]. Similar findings in humans have been recently confirmed by
Teerlink's group, however they reported 15 μMADMA incorporated in washed red blood cells
that were frozen at -20°C overnight and re-suspended in two volumes of water prior to analysis
[22]. Distinct from these reports based on whole blood, the total ADMA in PRBC’s in the cur-
rent study (Fig. 2) ranged from 42 μM on day four to 69 μM on day 28 of standard storage con-
ditions. This could reflect the greater red blood cell concentration (density) in these PRBC
samples compared to fresh whole blood. Had we similarly diluted our PRBC sample our higher
measured ADMA concentrations would have been diluted to approximately 18 μM, which is in
reasonably close agreement with Teerlink's group. However, in our study it is unclear what ef-
fects the blood draw and blood bank processing involved in preparing PRBCs might have had
on increasing the inhibitory methylarginines in the PRBC samples. For this study we did not
have access to pre-donation whole blood samples to determine if they contained even lower in-
hibitory methylarginines averages that would have been even closer to what the Teerlink’s
group obtained using fresh washed and diluted human blood. It is important to note that nei-
ther our laboratory nor Teerlink’s report repeated paired measurements of the total ADMA
and LNMMA in freshly drawn erythrocytes and then again in these same samples once they
are prepared for clinical use as PRBC. Such a paired analysis of fresh donor blood (prior to do-
nation) and once processed to PRBC’s would be required to determine if processing itself in-
creased the total inhibitory methylarginines content in the PRBCs.
It is also possible that protein arginine methyltransferase (PRMT) was active during storage
at 6°C, but data collected from the stored samples at 6° compared to -80°C (Figs. 2 and 3), sug-
gest that there was either little or no ongoing PRMT activity contributing to the methylated ar-
ginine pool, or that the methylated residues were eliminated at the same rate as they were
formed (e.g., by DDAH activity). Allowing that the 6° and -80°C total ADMA values were in-
distinguishable (Figs. 2 and 3) it is most likely that neither methylation nor DDAH hydrolysis
occurred during storage at either temperature. This does not, however, exclude the possibility
of protein modifications during storage that would predispose PRBC proteins to subsequent
hydrolysis once the product was introduced by transfusion into a critically ill patient’s elevated
proteolytic milieu.
Erythrocyte catalase as a potential source of ADMA
The Tsikas group using GC-MS/MS has shown that neither hemoglobin [23] nor albumin [24]
contain significant amounts of ADMA. Thus, we looked for red blood cell proteins that had a
high concentration of arginine residues. We measured red blood cell catalase protein in an at-
tempt to identify a dominant intra-erythrocyte ADMA reservoir. The extensive human red
blood cells proteome is not entirely characterized, so we chose catalase due to its relatively high
arginine content and its high intracellular solubility. Additionally, Yokoro et al.[25] detected
ADMA in carbonic anhydrase II and catalase in Sprague-Dawley rat RBC. Our data (please see
PRBC as Source of NOS Inhibition
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Table 1) reveal that erythrocyte catalase only accounts for a small fraction (1.8%) of total
ADMA available in PRBC. The NCBI analyses of arginine-rich erythrocyte proteins suggest
that superoxide dismutase and cytoskeletal proteins such as ankyrin and spectrin may also con-
tribute as methylarginines reservoirs, but these remain untested. Please see the “S1 Methods”
section titled "Methods for Evaluation of PRBC catalase as a source of ADMA" for
further discussion.
Free vs. Incorporated ADMA and LNMMA
The plasma concentration of free ADMA alone is traditionally used to reflect the capacity of
vascular NOS inhibition, yet it is also widely accepted that LNMMA (present at lower concen-
trations) is a nearly equipotent NOS inhibitor [4]. We submit that combining the free circulat-
ing ADMA plus LNMMA concentration, for a total inhibitory methylarginine concentration,
more accurately represents the systemic NOS inhibitory burden. It is possible that LNMMA's
role has been under appreciated since the historical, widespread use of LNMMA as an internal
HPLC standard has obviated reporting on its presence in plasma or protein hydrolysates as an
analyte of interest. We have eliminated this shortcoming from this study by using NG-mono-
ethyl-L-arginine monoacetate salt (MEA) as our internal HPLC standard. This permits assess-
ment of the total and free LNMMA in addition to the ADMA in blood products. While the
normal plasma levels of LNMMA are very low (0.08 μM) the potential releasable pool is very
high (58.9 μM) and similar to that of ADMA.
Mechanistically, it is the pool of free ADMA and LNMMA circulating in plasma that is
readily available to move by Y+ facilitated diffusion into vascular endothelial cells and inhibit
NOS [26]. Y+, or cationic amino acid transporters are present in both vascular endothelial [27]
and red blood cells [28] and support bidirectional movement of L-arginine and methylargi-
nines between intra and extracellular compartments [29]. The overall plasma steady state in-
hibitor concentration then is a function of the balance between addition to and removal from
this volume. The presumptive pathway for addition is posttranslational methylation of pro-
tein-incorporated arginine by PRMT [7]. Once arginine is methylated, the protein itself must
then be hydrolyzed to release the ADMA and LNMMA into the pool, as only free amino acids
can compete with arginine to inhibit NOS. Removal of inhibitory methylarginines from the
pool is more clearly defined and is primarily (~83%) driven by the action of DDAH [9, 10],
while only a minor fraction of the pool is cleared by the kidneys [30, 31].
Removal of inhibitory methylarginines from plasma pool
DDAH activity plays a major role in in vivo [9, 10] ADMA hydrolysis. Indeed, numerous labo-
ratories have attempted to address modulating the balance between formation and removal of
ADMA and LNMMA by identification of DDAH analogs as potential therapeutic derivatives
to reduce plasma ADMA concentrations by increased or restored ADMA hydrolysis. Thus, re-
storing or enhancing removal [32, 33] is a strategy for managing various pathological states
with elevated plasma ADMA and LNMMA.
It is less clear however whether DDAH hydrolysis is active in vitro, during storage or incu-
bation [21]. In our PRBC incubation protocols, no attempt was made to modify any ongoing
DDAH activity. However, our previous work with rat blood [11] demonstrated a robust, pre-
sumably DDAH-like activity during incubation when the samples were spiked to elevate start-
ing ADMA levels. In addition, 4124W (DDAH inhibitor) [34] or supplemental Zn [35]
decreased the disappearance of added ADMA further suggesting the presence of DDAH-like
activity. It is likely that in those studies the elimination of ADMA was more evident because
the higher substrate (ADMA) concentration was driving the ADMA hydrolysis reaction. In the
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present study it is possible that there was some undetected, ongoing DDAH-like activity that
was obscured by simultaneous release of “new” ADMA into solution. However, here we present
no evidence that human PRBCs contain DDAH—agreeing with a similar recent observation by
the Teerlink group [21, 22] using fresh human blood. While Kang [36, 37] reported the pres-
ence of DDAH in human blood that hydrolyzed both ADMA and LNMMA, Teerlink’s group
reported no increase in citrulline in incubated erythrocytes and they interpreted this as indica-
tive of no DDAH activity [22]. It is possible, however, that any citrulline resulting from the
DDAH hydrolysis of ADMA and LNMMA was simply converted back to arginine. Our current
data do not resolve this issue and ADMA-spiked PRBC supernatants would need to be evaluat-
ed to provide adequate resolution.
Balance of proteolytic release and elimination
The balance of normal rates of proteolytic release and subsequent elimination by hydrolysis
produce normal plasma concentrations for ADMA and LNMMA in humans, [38] rats, and
mice [39] that are sub-micromolar (0.1 to 1.0 μM). In multiple ischemic cardiovascular dis-
eases including stroke[40], coronary artery disease [41], and peripheral arterial occlusive dis-
ease[42], the pathological plasma levels of ADMA and LNMMA are higher and well within
range of their endothelial NOS inhibitory constants (Ki, 0.9 μM and 1.1 μM respectively [4])
thus establishing conditions necessary for NO dysregulation.
Release of inhibitory methylarginines in vitro by strong acid hydrolysis
vs. 37°C incubation
In our initial observation of freeze-thawed (lysed) rat whole blood (FTWB) we reported that
strong acid hydrolysis liberated a total of 43 μMADMA and incubation for 5h at 37°C released
enough free ADMA to increase its free concentration from 0.95 μM to 2.32 μM or more than
2.4 times baseline—yet we detected no ADMA change when fresh rat plasma alone was incubat-
ed [11]. In the same study, protease inhibitor cocktails markedly attenuated ADMA release sug-
gesting a proteolytic release mechanism. In patients with end stage renal disease and matched
hypertensive control subjects with normal renal function, we demonstrated similar plasma levels
to those found in rats for both total ADMA and incubation-induced release of ADMA [12].
Teerlink’s group has confirmed both the presence of protein incorporated ADMA in fresh
washed human erythrocytes and, using a similar incubation protocol, induced release of ADMA
that was attenuated by protease inhibitors [21]. In separate studies, serum albumin was found to
contain 0.3 nmol ADMA/g albumin while hemoglobin was reported to contain none [23, 24].
More recently Teerlink’s group [22] extended the incubation-release protocol to 18h and demon-
strated a sustained ADMA release that could account for 22% at 2h and 60% at 18h of the total
content released in their washed fresh erythrocyte preparation. While these studies point to the
erythrocyte as a significant source of ADMA and LNMMA, what was missing was an assessment
of the total content and release capability of commercial blood products (PRBC and fresh frozen
plasma). Thus, they too could not account for changes that might have occurred during sample
preparation and storage of red blood cells and plasma for transfusion. The magnitude of the re-
lease-response they report is comparable to what we observed. This suggests that the mecha-
nisms for release withstand a variety of experimental manipulations and processing procedures.
By extension, these likely also remain intact in the PRBC product used for clinical transfusion.
Inhibitory methylarginines in fresh frozen plasma
It appears that regardless of the species or method of preparation, erythrocytes are capable of
releasing significant quantities of endogenous NOS inhibitors. By contrast, incubation of
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thawed fresh frozen plasma alone at 37°C for 5h, failed to show any increase in free ADMA
(Fig. 3) supporting our initial observation using fresh rat plasma [11]. In this study, we initially
concluded that plasma either does not have the methylated proteins to be hydrolyzed or does
not contain active proteases to release the ADMA and LNMMA. A 1:1 dilution of PRBC with
plasma reduced the “PRBC-protein” but did not reduce overall release rates for ADMA. Either
additional substrate must have been available to react in the 1:1 mixture and/or greater hydro-
lytic activity was at work during this 5h period. Because incubation of plasma alone did not re-
lease inhibitory methylarginines it is most likely that plasma did not contain active proteolytic
enzymes at the time of incubation. We therefore conclude that the 1:1 mixture simply supplied
additional inhibitory methylarginines containing proteins for the PRBC-based proteolytic en-
zymes to hydrolyze. Perhaps if we diluted the PRBC supernatant with normal saline the release
of ADMA would have been proportionately reduced. Thus we conclude both PRBC and plas-
ma contain MA-substrates but only the PRBC appear to have active proteolytic enzymes neces-
sary for NOS inhibitor release from blood proteins.
Potential Adverse Consequences of Excess NOS Inhibition
In the vasculature, NO is formed by eNOS [43, 44] and is a naturally occurring, highly reactive,
and widely distributed signaling molecule. Endothelial cells contain NOS and their failure to
produce NO is widely associated with vascular endothelial dysfunction. Direct damage to en-
dothelial cells and or competitive inhibition of eNOS by ADMA or LNMMA reduces the tissue
and plasma concentration of NO and this contributes to cardiovascular pathologies character-
ized as endothelial dysfunction [45, 46]. Understanding the determinants of plasma ADMA
and LNMMA concentrations is essential to understanding endothelial dysfunction that, in
turn, is integral to understanding much of the pathophysiology of cardiovascular disease.
Mihout et al used an 8-week ADMA infusion in normal mice and induced glomerular and
renal vascular fibrosis with elevated collagen I & II and fibronectin consistent with the develop-
ment of atherosclerosis, cardiovascular disease and progression of renal disease [1]. Elevated
ADMA has been attributed to its impaired systemic clearance by DDAH, and overexpression
of DDAH reduces ADMA [47–49] attenuating pathological changes in otherwise normal mice.
We previously demonstrated short-term (60 min) ADMA infusion (0.0125 mgKg-1min-1) in
humans significantly increased plasma myeloperoxidase (MPO) a NO-oxidizing hemoprotein
with proinflammatory properties [3]. Richir et.al. linked onset of organ failure to a significant
increase in both mean arterial pressure and systemic vascular resistance and decrease in cardiac
output with acute ADMA infusions (increased plasma ADMA from 0.52 to 3.3 μM). Arginine
depletion via arginase coupled with ADMA infusion in the same study magnified these in-
creases [50]. Together, such studies point to a direct, causal role for elevated NOS inhibition by
ADMA in cardiovascular dysfunction. It is also possible that the loss of NO availability de-
scribed by both groups is due instead to increased release of endogenous inhibitors of NOS
(ADMA and LNMMA) given the elevated levels of proteolysis associated with hemolysis. In
addition hemoglobin scavenging of NO and RBC-derived arginase depletion of arginine (sub-
strate of NOS) have been identified as additional contributors to endothelial dysfunction.
Potential Hemolysis-dependent Disruption of NO Homeostasis by
Hemoglobin
Gladwin and Kim-Shapiro made a compelling argument that storage lesions might be ex-
plained by NO dysregulation attributable to impaired NOS activity. They focused on the inter-
action of free hemoglobin with NO causing hemolysis-dependent disruption of NO
homeostasis, increased NO catabolism and loss of NO-generating function [51, 52]. Stamler’s
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group published data [53–55] on the acute loss of S-nitrosohemoglobin (SNO-Hb) within 3h
of collection. Such a loss would be anticipated to result in a loss of NO bioavailability; perhaps
more importantly, they suggested that SNO-HB repletion might improve transfusion efficacy.
We agree that loss of NO availability and freed hemoglobin impairs NOS homeostasis and thus
contributes to storage lesions. Data from this current study show that the endogenous NOS in-
hibitors, ADMA and LNMMA, are present in high concentrations during storage and thus
could produce a protracted impairment of NOS activity when infused as a bolus and could pro-
duce ongoing NOS inhibition by continued release in vivo from fragile red blood cell disruption
and MPO release [3]. We anticipate that this accumulation of endogenous NOS inhibitors dur-
ing storage and continuing once infused would contribute more strongly to a sustained NOS
dysfunction and thus the overall adverse outcomes of transfusion of aged blood products. We
anticipate that infused NOS inhibition by ADMA and LNMMA is thus at a minimum comple-
mentary to increased NO catabolism in causing the storage lesion.
Potential Arginase Contribution to NOS Inhibition
Arginase eliminates arginine and is thus a possible additional contributor to reduced NO for-
mation. The limited availability of arginine would thus reduce NOS activity during storage.
Bernard and co-workers [56] demonstrated increased arginase activity in a leukoreduced red
blood cell preparation. The addition of nor-N-ω-OH-L-arginine, an irreversible arginase
blocker, decreased arginase activity. Reduced NOS substrate could reduce NO production.
However, when these units are infused they mix with the recipient’s normally abundant circu-
lating arginine. Thus, while it is likely that reduced free arginine could be an issue for NO for-
mation during storage, it is less apparent that the problem would persist upon transfusion.
Instead, we propose an exaggerated endogenous NOS inhibition due to a significant accumula-
tion of both ADMA and LNMMA during storage. In a transfusion, ADMA and LNMMA
would enter the recipient's blood and endothelial cells to inhibit eNOS. The transfused ADMA
and LNMMA would reduce NO production, and ongoing ADMA and LNMMA release would
sustain this inhibition. However, testing endothelial dysfunction in patient infusion protocols
was beyond the scope of this study.
Limitations of this study
To reduce baseline variability, we restricted our protein source to either fresh frozen plasma
from male donors or Red Blood Cells, Adenine—Saline Added, Leukocytes Reduced, Group O,
and Rh positive, from male donors. Even with these restrictions, the baseline oxidant milieu of
the donor blood was unknown and hence not factored into the analysis. Using only male do-
nors allowed us to avoid potential sex-dependent differences in protease profile or proteolytic
background in donor blood but none of the other likely modulators of protein turnover were
assessed. In addition, when we incubated fresh human male blood, we found it had significant-
ly greater ADMA release than that of females [12]; so, sex-dependent differences need further
evaluation in controlled clinical trials assessing the endogenous NOS inhibitory status of the
blood donor.
This study has not attempted to demonstrate the adverse consequences of NOS inhibitor in-
fusion nor quantitate the NOS inhibitor burden once the blood product is infused. Instead, it
demonstrates the substantial NOS inhibitory concentration of products used in transfusion
medicine. We have demonstrated that PRBC have the potential to release two orders of magni-
tude greater than normal quantities of the endogenous NOS inhibitors ADMA and LNMMA.
These inhibitory methylarginines are incorporated in blood proteins and at normal body tem-
peratures are released from PRBCs by proteolysis. When PRBCs are infused, we would
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anticipate at least a transient increase in endothelial dysfunction and reduced plasma NO avail-
ability, if not frank cardiovascular pathology. In a healthy individual, aggressive inhibitory
methylarginine clearance by endogenous DDAHmight mitigate this hazard. However, in indi-
viduals with high proteolytic stress, or elevated proinflammatory cytokines, the incremental
burden of infused ADMA and LNMMA via a PRBC transfusion could pose a significant and
previously unidentified cardiovascular risk.
Supporting Information
S1 Methods. File contains detailed methodology of methylarginine sample preparation and
HPLC separation and detection, hemoblobin measurement, and PRBC catalase evaluation.
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